Novo nordisk a/s: monlunabant phase 2a trial in obesity successfully completed

BagsvÆrd, denmark, 20 september 2024 – novo nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (cb1) inverse agonist. monlunabant, formerly inv-202, was part of the acquisition of inversago pharmaceuticals inc. announced in august 2023 [link].
NVO Ratings Summary
NVO Quant Ranking